Global Growth Hormone Deficiency Market Size, Share, Growth

Q: What is the global market size of Growth Hormone Deficiency Market?

Global Growth Hormone Deficiency Market size was valued at USD 3.47 billion in 2022 and is poised to grow from USD 3.70 billion in 2023 to USD 6.12 billion by 2031, growing at a CAGR of 6.50% in the forecast period (2024-2031).

Growth Hormone Deficiency Market Competitive Landscape

The competitive environment of the global Growth Hormone Deficiency market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor.

Top Player’s Company Profiles

Pfizer (US)

Eli Lilly and Company (US)

Genentech (US)

Novo Nordisk (Denmark)

Merck & Co. (US)

Sandoz International (Switzerland)

Ferring Pharmaceuticals (Switzerland)

Ipsen (France)

Teva Pharmaceutical Industries (Israel)

GeneScience Pharmaceuticals (China)

LG Chem (South Korea)

Anhui Anke Biotechnology Group (China)

Biopartners (Switzerland)

Procter & Gamble (US)

Endo International (Ireland)

LG Life Sciences (South Korea)

Versartis (US)

Opko Health (US)

LG Electronics (South Korea)

Rani Therapeutics (US)

FAQs

Growth Hormone Deficiency Market size was valued at USD 3.47 billion in 2022 and is poised to grow from USD 3.70 billion in 2023 to USD 6.12 billion by 2031, growing at a CAGR of 6.50% in the forecast period (2024-2031).

The competitive environment of the Growth Hormone Deficiency market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. 'Pfizer (US)', 'Eli Lilly and Company (US)', 'Genentech (US)', 'Novo Nordisk (Denmark)', 'Merck & Co. (US)', 'Sandoz International (Switzerland)', 'Ferring Pharmaceuticals (Switzerland)', 'Ipsen (France)', 'Teva Pharmaceutical Industries (Israel)', 'GeneScience Pharmaceuticals (China)', 'LG Chem (South Korea)', 'Anhui Anke Biotechnology Group (China)', 'Biopartners (Switzerland)', 'Procter & Gamble (US)', 'Endo International (Ireland)', 'LG Life Sciences (South Korea)', 'Versartis (US)', 'Opko Health (US)', 'LG Electronics (South Korea)', 'Rani Therapeutics (US)'

Human growth hormone (HGH), also referred to as somatotropin, plays a pivotal role in human development by facilitating cell growth, division, and regeneration. Insufficient synthesis of growth hormone (GH) by the pituitary gland leads to a deficiency of hGH in humans. The remedy for this deficiency involves the subcutaneous administration of recombinant human growth hormone. Genetic disorders such as Prader-Willi syndrome and Turner syndrome, characterized by delayed puberty and shorter stature, can also contribute to growth hormone insufficiency.

The pharmaceutical industry is poised for tremendous growth due to rapid advancements in drug delivery. Pioneering innovations such as wearables, needleless devices and autoinjectors have been central, improving the high level of comfort and patient compliance with growth hormone therapy delivery Notably the rapid availability of long-acting drugs and implantable devices is feasible, allowing for longer delivery times and longer delivery of growth hormone to reduce dose frequency Not that these improvements provide not only improve clinical outcomes, but improve the overall patient experience, expanding the availability and efficacy of growth hormone therapies.

By 2022, North America emerged as the leading country in the growth hormone therapy market, commanding a substantial 42.27% of the total revenue, This leadership position can be attributed to improved health awareness among the population , outstanding government programs and good reimbursement programs in the region With more money, organizations dedicated to increasing awareness and treatment in the region are expected to contribute significantly to expansion of the market reaffirming the important role of North America in the development of growth hormone therapies.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Growth Hormone Deficiency Market Size, Share, Growth Analysis, By Application(Pediatric growth hormone deficiency, Idiopathic short stature), By Route of Administration(Subcutaneous, Intramuscular), By Type(Norditropin, Genotropin) - Industry Forecast 2024-2031

Growth Hormone Deficiency Market Competitive Landscape

Growth Hormone Deficiency Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Growth Hormone Deficiency Market Size, Share, Growth Analysis, By Application(Pediatric growth hormone deficiency, Idiopathic short stature), By Route of Administration(Subcutaneous, Intramuscular), By Type(Norditropin, Genotropin) - Industry Forecast 2024-2031

Growth Hormone Deficiency Market Competitive Landscape

Growth Hormone Deficiency Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Growth Hormone Deficiency Market?

Who are the key vendors in the Growth Hormone Deficiency Market?

What is the key driver of Growth Hormone Deficiency Market?

What is the key market trend for Growth Hormone Deficiency Market?

Which region accounted for the largest share in Growth Hormone Deficiency Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300